Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
264K
-
Shares change
-
+76.7K
-
Total reported value, excl. options
-
$3.93M
-
Value change
-
+$1.02M
-
Number of buys
-
2
-
Number of sells
-
-2
-
Price
-
$14.93
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2023
4 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2023.
NovoCure Ltd - Common Stock (NVCR) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 264K shares
of 112M outstanding shares and own 0.24% of the company stock.
Largest 10 shareholders include FMR LLC (16M shares), VANGUARD GROUP INC (9.76M shares), Capital International Investors (8.86M shares), BlackRock Inc. (8.79M shares), BAILLIE GIFFORD & CO (4.84M shares), STATE STREET CORP (3.86M shares), Capital World Investors (3.28M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.25M shares), TWO SIGMA ADVISERS, LP (1.63M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.59M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.